Latest Breaking News On - Mark litton - Page 5 : comparemela.com

Athira Pharma Inc (ATHA) Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer s Patients

Athira Pharma Inc (ATHA) Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer s Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMark littonJulie rathbun athira pharmaHans moebiusNational institutes of healthAthira pharma incAlzheimer disease cooperative studyExchange commissionSecurities exchangeGlobal statistical testDisease assessment scale cognitive subscaleDisease cooperative study activitiesDaily livingChief medical officerChief executive officerNational institute

INVESTIGATION ALERT: Kaskela Law LLC Announces Shareholder

PHILADELPHIA, Oct. 16, 2022 (GLOBE NEWSWIRE) Kaskela Law LLC announces that it is investigating Athira Pharma, Inc. (“Athira” or the “Company”).

Newtown squareUnited statesMark littonAthira pharmaAdrienne bellExchange commissionAthira pharma incKaskela lawDoctoral research while at washington state universityLeadership responsibilities of companyPharma chief operating officerAssumes day to leadership responsibilitiesLeen kawas placedTemporary leave pending board reviewActions stemmingDoctoral research while

Athira Pharma (ATHA) Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer s Patients

Athira Pharma (ATHA) Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer s Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMark littonHans moebiusAthira pharma incNational institutes of healthGlobal statistical testChief medical officerChief executive officerMini mental state examClinical dementia ratingNational instituteNational institutes

Athira Pharma (ATHA) Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer s Patients

Athira Pharma (ATHA) Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer s Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMark littonHans moebiusAthira pharma incAlzheimer association international conferenceNational institutes of healthChief medical officerMild to moderate alzheimerFirst resultsWeek phaseAssociation international conferenceMini mental state examClinical dementia ratingLeast squaredScientific advisory boardData safety monitoring board

Athira Pharma Presents Data from ACT-AD Phase 2

Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of.

United statesMark littonAthira pharmaJulie rathbunHans moebiusAlzheimer association international conferenceNational institutes of healthExchange commissionAthira pharma incAlzheimer disease cooperative studySecurities exchangeChief medical officerMild to moderate alzheimerFirst resultsWeek phaseAssociation international conference